Preview

Pharma Update 08 Nov 2014

Good Essays
Open Document
Open Document
766 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Pharma Update 08 Nov 2014
November 08, 2014

Pharma Sector Update
(Sector Analysts: Kanika Singh, Neha Kumar and Ravi Karanam)

USFDA revokes Ranbaxy's 180-day exclusivity on sale of two generic drugs in US, grants approval to Dr. Reddy for one of them
The USFDA has reverted its tentative approvals granting Ranbaxy six-months sales exclusivity of the generic versions of Roche's anti-viral drug Valcyte and AstraZeneca's heartburn pill Nexium. Ranbaxy had first-to-file status on both these drugs and it was expected to earn USD 60 million and USD 180 million from the generic versions of Valcyte and Nexium respectively in the exclusive sale period. The USFDA said that its original decision of granting tentative approvals were erroneous because of the compliance status of the facilities mentioned in the ANDAs (Abbreviated New Drug Application) filed by Ranbaxy, as a result of which in FDA's view, Ranbaxy had forfeited its eligibility for 180-day exclusivity for its ANDA for Valcyte. The news could hit the shares of Ranbaxy and Sun Pharma, already under CCI's scanner for the $4 billion M&A deal, the decision for which is expected this month. Earlier in the week,Ranbaxy had received approval from the USFDA to manufacture and market Fenofibrate capsules, used for lowering high cholesterol and triglyceride levels in the blood.
The revocation of Ranbaxy's 180-day exclusivity on sale has turned out to be a positive news for Dr. Reddy's Laboratories which has been granted the final approval by USFDA to make cheaper versions of Valcyte. The company is expected to launch the drug shortly in the US market.
ROC questions Plethico Pharmaceuticals over complaints from investors on the fixed deposit schemes
The Registrar of Companies (ROC),Gwalior is inspecting the books of accounts of the Indore-based Plethico Pharmaceuticals, following hundreds of complaints received by the investor grievance cell of the corporate affairs ministry for almost a year. The investors claimed that

You May Also Find These Documents Helpful

  • Good Essays

    Merck and Vioxx

    • 972 Words
    • 4 Pages

    In May of 1999, the FDA approved the use of rofecoxib. Marketed under the name of Vioxx, rofecoxib was manufactured and distributed by Merck, a large pharmaceutical company. Doctors prescribed the drug as a non-steroidal anti-inflammatory and prescription painkiller. Five years after its release, rofecoxib was withdrawn because of a study that showed the drug more than doubled the risk of heart attack or stroke. Because of Merck’s ongoing and increasing knowledge of the dangerous effects of the drug while continuing to distribute rofecoxib, Merck should be held accountable for acting unethically.…

    • 972 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    The Medicines Company

    • 868 Words
    • 5 Pages

    The Medicines Company Case Write-Up: Terence Cho, Felipe Duarte, Aleks Loiko, Robert Shaw, and James Wang…

    • 868 Words
    • 5 Pages
    Powerful Essays
  • Better Essays

    Fda Research Paper

    • 2368 Words
    • 10 Pages

    Americans must wait up to 19 years after a discovered treatment before they can participate in benefits of a new medication (Philipson & Sun, 2008). The regulatory process drug manufacturers need to endure before releasing potentially life-saving medication is an extremely expensive, time-consuming process. The Center for Drug Evaluation and Research (CDER) is the main department of the Food and Drug Administration (FDA) responsible for the safety of drugs (both prescription and over-the-counter) sold in the United States (Food and Drug Administration, 2011). This department scrutinizes the testing of new drugs and determines if they are safe and effective before distribution. They do not perform in-house testing themselves; they only evaluate the testing done by the manufacturer to make sure the drug claim is accurate and that the benefits of the medication out way the side-effects (Food and Drug Administration, 2011). Whereas the FDA’s regulation and oversight protects dangerous products from circulation, the approval process hinders manufacturers’ ability to release drugs in a timely manner because of the legal and cost liability, thus preventing the availability of treatment to Americans.…

    • 2368 Words
    • 10 Pages
    Better Essays
  • Good Essays

    In 2011, the patent for Lipitor expired and many companies have begun to make generic versions. Ranbaxy has been making a generic brand of the medicine since late last year. Ranbaxy recalled the medicine out of caution with the knowledge of the FDA. The FDA has been carefully watching Ranbaxy since the investigation and sanctions back in 2006. Federal investigators found that Ranbaxy did not test the shelf life and safety factors of drugs and lied about results. Ranbaxy signed a decree that stated that they would improve manufacturing procedures, ensure product data and make sure for five years a third party would be used to review the company. Ranbaxy had $500 million set aside to cover potential criminal and civil liability. The company conducted a two week investigation of how the glass particle was found in the medication. There were no injuries caused by the tainted medicine and the problem of how the glass particles were found. Given its high volume of need for the drug there may be shortage of the drug over the next two weeks. Pharmacies and wholesalers will be the two most impacted (Walton,…

    • 736 Words
    • 3 Pages
    Good Essays
  • Best Essays

    References: David, F.I. & PL, J. (2013). Compound Pharmacy Regulatory Update: Senate to Vote on…

    • 3430 Words
    • 14 Pages
    Best Essays
  • Good Essays

    Biomax Case Summary

    • 1049 Words
    • 5 Pages

    The Company's primary strategy is to get those prescriptions surrendered by other pharmaceutical organizations. Despite the fact that the Company has received 4 standards to screen among the competitors, in any case it confronts the potential danger of disappointment. Drug organizations relinquished these items for a mixture of great reason including security, viability and benefit potential. Why does the Medicines Company have the Golden Finger? There is no such ensure that items which consent to the 4 criteria will end up being a blockbuster product. The Company seems to fail to offer an agreeable advertising arrangement for Angiomax and other future medications that are coming to company regarding to FDA. So we should stay sensible about…

    • 1049 Words
    • 5 Pages
    Good Essays
  • Good Essays

    Enabling mighty competition between commonplace drug treatments and patent-expired fashioned brands is relevant to decreasing pharmaceutical charges and stimulating innovation. However, this mentioned, there are numerous troubling problems surrounding general medicines because of the convenient access to an abundance of illegal generics on the internet breaking the patent ownership and the unregulated companies that produce and supply them. At the same time familiar medicines will have to be approved identical types of depended on drugs, providing the equal fine, safety and efficacy because the normal, that is commonly no longer the case. A conventional drug must endure strict scrutiny before it is licensed and given market approval with the aid of countrywide medicines authorities. In brief, common medicines will have to comply with the same strict standards of great, safety and efficacy as usual pharmaceutical…

    • 490 Words
    • 2 Pages
    Good Essays
  • Satisfactory Essays

    Merck Executive Summary

    • 496 Words
    • 2 Pages

    A decision will be madeusing both qualitative factors and quantitative analysis. Qualitatively, this opportunity is positive for both Merck and LAB. Licensing this drug will allow Merck to insert a newly patented compound into the market and to bypass the discovery and preclinical testing phases. By being able to skip those two phases, Merck can go straight to clinical testing saving it six to seven years, which helps Merck deal with its patent life cycle in a more effective manner. LAB has never had a drug successfully complete the FDA approval process in its 15-year history. Its stock price had also fallen by 30% after its most recent FDA denial. Therefore, by licensing this Davanrik to Merck, LAB would be able to receive some much-needed cash. A successful transaction between Merck and LAB could also lead to future opportunities.…

    • 496 Words
    • 2 Pages
    Satisfactory Essays
  • Good Essays

    PharmaSim Project

    • 1031 Words
    • 5 Pages

    The objectives and goals of Allstar are to look for new opportunities in emerging market with support from healthy and growing cash flow, to introduce new product, to maintain leadership and to maintain long-term profitability and market share in an increasingly competitive and changing environment.…

    • 1031 Words
    • 5 Pages
    Good Essays
  • Satisfactory Essays

    The FDA investigated if results used to approve Xarelto in the clinical trial (ROCKET AF trial) were genuine and still valid. The clinical trial, was to compare the effectiveness of Xarelto to those of Warfarin and showed…

    • 528 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Big Pharma Research Paper

    • 840 Words
    • 4 Pages

    Big Pharma, or the pharmaceutical industry's giant corporations, have earned record profits, falsified clinical trial data and corrupted the healthcare industry according to many industry critics including a recent report posted on Globalresearch.ca.[1] The industry's story parallels the history of other corporate monopolies such as Big Oil, the Railroad Industry, Big Agriculture, banking interests and other industrial giants. In fact, one of the primary founders of privatized health care--the Rockefeller family--has been accused of multiple monopolistic and ethical lapses in banking and other industries. Big Pharma financed many of the medical advances made since the…

    • 840 Words
    • 4 Pages
    Good Essays
  • Satisfactory Essays

    The purpose of this paper is to analyze federal antitrust enforcers are investigating whether a multinational pharmaceutical company has attempted to minimize the impact of generic competition to one of its most profitable prescription drugs. This anti-depressant drug is the company’s best seller, with sales last year of $2.11 billion, representing a 22% increase from the year before. I will review whether pharmaceutical companies have engaged in activities that will prevent generic brands to the prescription drug from entering the market. Federal Trade commission is challenging a practice among brand-name and generic drug manufacturers to agree to delay the introduction of the…

    • 686 Words
    • 3 Pages
    Satisfactory Essays
  • Better Essays

    It claimed that the above property made it a new and superior product as it increased its property of storage and process. Its claim for patent was rejected by Chennai Patent Office on grounds of lacking novelty, innovative step and being unpatentable in view of Section 3(d). Then Novartis challenged the decision before the Honorable Madras High court in a writ petition. It claimed before the High Court that Indian Patent law is not consistent with World Trade organization (WTO) Rules. It appealed the court to invalidate Section 3(d). The High Court rejected this plea and transferred the matter to the ‘Intellectual Property Appellate Board’ which also rejected its patent as it found it to be unpatentable under Section 3(d) of the Indian Patents Act. IPAB observed that the drug does not have a new molecule but has a modified version of a known compound for which Novartis failed to show any increased efficacy. But IPAB had also observed that Novartis satisfied the other requirements for patent, i.e. ‘novelty’ and ‘non obviousness to person skilled in art ‘. Based on its observations, IPAB rejected the application on 26 June, 2009.…

    • 2434 Words
    • 10 Pages
    Better Essays
  • Satisfactory Essays

    2. How did Zocor neutralize the entry strategy of Vidastat in the anti-cholesterol market? If you were the product manager for Zocor, what might your strategy have been if you had been faced with the same situation?…

    • 327 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    FMB&T

    • 269 Words
    • 2 Pages

    There are two main points in this case. The first one is that AH Biotech will be the first to bring that particular drug to the market faster and cheaper. The second one is that the company considers the problem of offering people dramatic relief then snatches it away after getting approved. It is an ethical dilemma that the company faces.…

    • 269 Words
    • 2 Pages
    Satisfactory Essays